Participation of the Elderly Population in Clinical Trials: Barriers and Solutions

Abstract

Background

Despite the fact that cancer disproportionately affects the elderly, most participants of clinical cancer trials are relatively young. This misrepresentation greatly affects the oncology treatment of the elderly population (> 65 years of age). Few studies have attempted to identify the problems related to discrepancy based on age for clinical trial participation.

Methods

A literature review was performed to identify barriers and solutions to enrollment of elderly persons for clinical cancer trials.

Results

Physician-related barriers include perception about treatment tolerance, drug metabolism, a lack of evidence for efficacy, and age bias. Lack of autonomy, concerns about quality of life and toxicities, accessibility to clinical trials, and logistical and financial difficulties are common patient-related barriers. Trial-related barriers include eligibility criteria based on performance status, organ dysfunction, and the presence of comorbidities. Solutions, such as improved communication, and coordinating logistical challenges may help overcome some of these challenges. Studies designed for the geriatric population could modify the perception and behavior of health care professionals and improve patient participation in clinical trials.

Conclusions

Implementing some of these solutions and increased research may help overcome shortfalls in elderly enrollment, thus allowing for more effective treatment of older patients.

References

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.

Mariotto

A.B.

, Yabroff

K.R.

, Shao

. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2): 117–128.

Knickman

J.R.

, Snell

E.K.

. The 2030 problem: caring for aging baby boomers. Health Serv Res. 2002; 37(4): 849–884.

Janssen-Heijnen

M.L.

, Houterman

, Lemmens

V.E.

. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005; 55(3): 231–240.

Lara

P.N.

Jr , Higdon

, Lim

. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001; 19(6): 1728–1733.

Unger

J.M.

, Coltman

C.A.

Jr , Crowley

J.J.

. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006; 24(1): 141–144.

Kimmick

G.G.

, Peterson

B.L.

, Kornblith

A.B.

. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol. 2005; 23(10): 2201–2207.

Hutchins

L.F.

, Unger

J.M.

, Crowley

J.J.

. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27): 2061–2067.

Aapro

M.S.

, Köhne

C.H.

, Cohen

H.J.

. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005; 10(3): 198–204.

10.

Rao

, Cohen

H.J.

. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004; 2004(32): 150–157.

11.

Bernabei

, Gambassi

, Lapane

; SAGE Study Group. Management of pain in elderly patients with cancer. Systematic assessment of geriatric drug use via epidemiology [published correction appears in JAMA. 1999;281(2): 136]. JAMA. 1998; 279(23): 1877–1882.

12.

Lewis

J.H.

, Kilgore

M.L.

, Goldman

D.P.

. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21(7): 1383–1389.

13.

Trimble

E.L.

, Carter

C.L.

, Cain

. Representation of older patients in cancer treatment trials. Cancer. 1994; 74 (7 suppl): 2208–2214.

14.

Kemeny

M.M.

, Peterson

B.L.

, Kornblith

A.B.

. Barriers to clinical trial participation by older women with breast cancer [published correction appears in J Clin Oncol. 2004;22(23): 4811]. J Clin Oncol. 2003; 21(12): 2268–2275.

15.

Yee

K.W.

, Pater

J.L.

, Pho

. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003; 21(8): 1618–1623.

16.

Hurria

, Togawa

, Mohile

S.G.

. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29(25): 3457–3465.

17.

Zafar

S.F.

, Heilbrun

L.K.

, Vishnu

. Participation and survival of geriatric patients in phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. J Geriatr Oncol. 2011; 2(1): 18–24.

18.

Palaia

, Loprete

, Musella

. Chemotherapy in elderly patients with gynecological cancer. Oncology. 2013; 85(3): 168–172.

19.

Giovanazzi-Bannon

, Rademaker

, Lai

. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994; 12(11): 2447–2452.

20.

LoConte

N.K.

, Smith

, Alberti

. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010; 65(4): 775–780.

21.

Javid

S.H.

, Unger

J.M.

, Gralow

J.R.

. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012; 17(9): 1180–1190.

22.

Townsley

C.A.

, Selby

, Siu

L.L.

. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23(13): 3112–3124.

23.

Foster

J.A.

, Salinas

G.D.

, Mansell

. How does older age influence oncologists’ cancer management? Oncologist. 2010; 15(6): 584–592.

24.

Townsley

C.A.

, Chan

K.K.

, Pond

G.R.

. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006; 6: 34.

25.

Jenkins

, Farewell

; TTT Steering Committee. Drivers and barriers to patient participation in RCTs. Br J Cancer. 2013; 108(7): 1402–1407.

26.

Umutyan

, Chiechi

, Beckett

L.A.

. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008; 112(1): 212–219.

27.

Garrido-Laguna

, Janku

, Vaklavas

. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012; 118(5): 1422–1428.

28.

van Heeckeren

W.J.

, Fu

, Barr

P.M.

. Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. J Geriatr Oncol. 2011; 2(3): 215–221.

29.

Baggstrom

M.Q.

, Velcheti

, Malik

. Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer: P1-250. J Thorac Oncol. 2007; 2(8): S838.

30.

Hempenius

, Slaets

J.P.

, Boelens

M.A.

. Inclusion of frail elderly patients in clinical trials: solutions to the problems. J Geriatr Oncol. 2013; 4(1): 26–31.

31.

Herrera

A.P.

, Snipes

S.A.

, King

D.W.

. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010; 100(Suppl 1): S105–S112.

32.

Kornblith

A.B.

, Kemeny

, Peterson

B.L.

. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002; 95(5): 989–996.

33.

Yourman

L.C.

, Lee

S.J.

, Schonberg

M.A.

. Prognostic indices for older adults: a systematic review. JAMA. 2012; 307(2): 182–192.

34.

Extermann

, Boler

, Reich

R.R.

. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012; 118(13): 3377–3386.

35.

National Institues of Health (NIH) Revitalization Act. Subtitle B: §131-133; 1993.

36.

Extermann

, Chen

, Cantor

A.B.

. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002; 38(11): 1466–1473.

37.

Hamaker

M.E.

, Stauder

, van Munster

B.C.

. On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Ann Oncol. 2014; 25(3): 675–681.